Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MRKR | US
0.11
3.14%
Healthcare
Biotechnology
30/06/2024
30/08/2024
3.61
3.50
3.61
3.40
Marker Therapeutics Inc. a clinical-stage immuno-oncology company engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing MT-401 which is in Phase 2 clinical trial for the treatment of post-transplant AML; MT-401-OTS for the treatment of AML; and MT-601 for the treatment of pancreatic cancer and lymphoma. Marker Therapeutics was founded in 1999 and is headquartered in Houston Texas.
View LessStrong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
58.1%1 month
77.1%3 months
89.6%6 months
74.7%-
-
3.32
-
-
-0.22
3.41
-
-11.79M
32.21M
32.21M
-
-197.40
-
53.30
-71.74
2.98
1.26
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.85
Range1M
1.96
Range3M
2.84
Rel. volume
0.59
Price X volume
55.29K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Fortress Biotech Inc | FBIOP | Biotechnology | 6.5791 | 35.32M | -1.07% | n/a | 494.61% |
Eyenovia Inc | EYEN | Biotechnology | 0.5501 | 35.24M | 2.78% | n/a | -662.22% |
Cue Biopharma Inc | CUE | Biotechnology | 0.7225 | 35.14M | 0.21% | n/a | 52.09% |
ARCA biopharma Inc | ABIO | Biotechnology | 2.4 | 34.82M | -4.00% | n/a | 0.07% |
Surrozen Inc. Common Stock | SRZN | Biotechnology | 10.638 | 34.10M | 7.02% | n/a | 35.73% |
Clene Nanomedicine Inc | CLNN | Biotechnology | 5.27 | 34.10M | -2.04% | n/a | -6472.02% |
Anthem Inc. CORP UNIT 050118 | ANTX | Biotechnology | 1.13 | 33.72M | 0.00% | n/a | 0.00% |
Curis Inc | CRIS | Biotechnology | 5.525 | 33.03M | 0.27% | n/a | -6039.91% |
Immuneering Corporation Class A Common Stock | IMRX | Biotechnology | 1.11 | 32.92M | -4.31% | n/a | 6.50% |
Moolec Science SA Ordinary Shares | MLEC | Biotechnology | 0.8701 | 32.59M | 0.01% | n/a | 209.19% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.6131 | 18.67M | -4.20% | n/a | 204.46% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.391 | 3.72M | -6.28% | n/a | 19.98% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.45 | 3.70M | 13.28% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.47 | 2.11M | -7.84% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.22 | 0.97 | Cheaper |
Ent. to Revenue | 3.41 | 3,681.29 | Cheaper |
PE Ratio | - | 39.83 | - |
Price to Book | 3.32 | 14.54 | Cheaper |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 89.62 | 76.13 | Par |
Debt to Equity | - | -2.05 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 32.21M | 4.04B | Emerging |